Excerpt

This guideline is relevant to all healthcare professionals who come into contact with patients with colorectal cancer or suspected of having colorectal cancer, as well as to the patients themselves and their carers. It is also expected that the guideline will be of value to those involved in clinical governance in both primary and secondary care to help ensure that arrangements are in place to deliver appropriate care for the population covered by this guideline.

Contents

• Key priorities for implementation
• Key research recommendations
• List of all recommendations
• Methodology
• Algorithms
• 1. Epidemiology
  • 1.1 Introduction
  • 1.2 Risk factors for colorectal cancer
  • 1.3 Incidence
  • 1.4 Mortality
  • 1.5 Survival
  • 1.6 Prevalence
  • References
• 2. Investigation, diagnosis and staging
  • 2.1 Diagnostic investigations
  • 2.2 Staging of colorectal cancer
  • References
• 3. Management of local disease
  • 3.1 Preoperative management of the patient’s primary tumour
  • 3.2 Colonic stents in acute large bowel obstruction
  • 3.3 Stage I colorectal cancer
  • 3.4 Laparoscopic surgery
  • 3.5 Adjuvant chemotherapy in rectal cancer
  • 3.6 Adjuvant chemotherapy for high-risk stage II colon cancer
  • 3.7 Adjuvant chemotherapy for stage III colon cancer
  • References
• 4. Management of metastatic disease
  • 4.1 Management of patients presenting in stage IV
  • 4.2 Imaging hepatic metastases
  • 4.3 Imaging extra-hepatic metastases
  • 4.4 Chemotherapy for advanced and metastatic colorectal cancer
  • 4.5 Biological agents in metastatic colorectal cancer
  • 4.6 Adjuncts to chemotherapy in unresectable metastatic disease
  • References
• 5. Ongoing care and support
  • 5.1 Follow-up after apparently curative resection
  • 5.2 Information about bowel function
  • References
• 6. PROMs for colorectal cancer patients
• Appendices
  • Appendix 1 Summary of the 5th edition of the TNM staging system for colorectal cancer and comparison with Dukes’ stage
  • Appendix 2 Mixed treatment comparison and cost-effectiveness analysis for sequences of oxaliplatin and irinotecan-based chemotherapy in the treatment of advanced and metastatic colorectal cancer
  • Appendix 3 Abbreviations
  • Appendix 4 Glossary
  • Appendix 5 Guideline scope
  • Appendix 6 People and organisations involved in production of the guideline
• Evidence Review
  • 2 Investigation, diagnosis and staging
  • 3 Management of Local Disease
  • 4 Management of Metastatic Disease
  • 5 Ongoing Care and Support
  • Appendix 1 Search strategies
  • Appendix 2 Economic Plan